Please login to the form below

Not currently logged in
Email:
Password:

Wyeth rated top pharmaceutical company by Wall Street

The Wall Street Journal 'Patent Scorecard' has ranked Wyeth first among 35 global pharmaceutical companies.

The Wall Street Journal 'Patent Scorecard' has ranked Wyeth first among 35 global pharmaceutical companies.

Wyeth outperformed the industry average by more than two fold on the Research Intensity measure. The Scorecard also compares stock performance for the leading company compared with the industry.

In FY06, Wyeth spent approximately USD 3.1bn on R&D with programmes focused on small molecules, vaccines and biotechnology.

The company is exploring more than 60 new therapies for diabetes, breast cancer, multiple sclerosis, HIV and schizophrenia. It is also the only major pharmaceutical company exploring three technical platforms for Alzheimer's disease therapeutics: small molecules, biotechnology proteins and vaccines.

The US-based pharmaceutical firm was evaluated on patent-based intellectual property, as measured by indicators including patents granted; quality of patents; Science Strength, or the degree to which a company's patent portfolio is linked to core science; Research Intensity, a comparative measure of the level of basic research; and Innovation Cycle Time, or the speed at which research results in patent assets.

Since Wyeth adopted an enhanced research and development productivity model in 2001, it has advanced 75 new molecular entities from discovery research into development, including 15 in 2006 alone; filed more than 60 investigational new drug applications, including 12 in 2006; and filed four major New Drug Applications in 2006.

10th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Four Health

Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...